Cantor Fitzgerald Downgrades Soleno Therapeutics to Neutral, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 91.3%

Neg 91.3% Neu 0% Pos 0%

Cantor Fitzgerald analyst Kristen Kluska downgrades Soleno Therapeutics (NASDAQ:SLNO) from Overweight to Neutral and lowers the price target from $123 to $53.